MTRC starts a subscription service with info about initiated and published Med Tech and IVD HTAs in Europe and globally

27

Jul 2020

For the last three years, MTRC maintained a be-weekly newsletter with information about reimbursement and market access changes in European countries.

From July 2020, we are extending this activity with an introduction of the paid subscription service HTA Alerts.

HTA Alerts is a subscription service with email alerts about initiated or published health technology assessments of medical devices and in-vitro diagnostic tests from 56 HTA organizations globally.

Key features:

  • Global coverage: the service includes key HTA organizations in Europe and globally (Australia, Brazil, Canada, Malaysia, Mexico, Singapore, Thailand and USA). In total, 56 active HTA organizations from 22 countries, producing Med Tech-related HTA reports, are included
  • All types of HTA organizations are included: the service includes international (e.g., EUnetHTA, national, regional, and hospital-based HTAs). The service includes 56 organizations
  • Timely alerts with essential information: alerts about initiated or published HTAs are sent to email every 2 weeks. For each report, a title, brief summary (if available) and the link are provided
  • All reports are classified according to 31 Technology Groups: the service helps to focus only on technologies of interest (e.g., cardiovascular or neuromodulating devices) and avoid wasting time on not relevant reports
  • Customized alerts and unlimited number of subscribers: All reports are customized based on the client's preferences about geographical and technological coverage. Number of enrolled subscribers from one company is unlimited
  • Reports are developed using a manual search: We do not trust search robots to identify and classify relevant information. The search and categorization of identified reports is performed manually by MTRC analysts

Benefits for our clients include:

  • Timely access to essential information: You can be the first to know about important developments for technology within the company and with your competition
  • Cost-effective approach: No single Med Tech company can afford such a massive screening and monitoring activity. You outsource an essential function of keeping the company up-to-date in a very cost-effective manner
  • Ability to engage with HTA stakeholders: By knowing about initiated assessment, you can engage with HTA bodies in a timely manner to provide relevant information about your technology to increase chances of more unbiased assessment and positive result of HTA
  • Customized information: You only get access to HTA information for countries (e.g., EMEA only) and technologies (e.g., peripheral vascular) of relevance to your position

Learn more and request a quote here.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more